Over the past 3 months, 14 analysts have published their opinion on Regeneron Pharmaceuticals REGN stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

In the last 3 months, 14 analysts have offered 12-month price targets for Regeneron Pharmaceuticals. The company has an average price target of $920.0 with a high of $1045.00 and a low of $800.00.

Get a quick summary of 14 analysts' ratings for Regeneron Pharmaceuticals over the last 3 months. More bullish views suggest a positive outlook, while more bearish views imply a negative sentiment.

This current average has increased by 4.74% from the previous average price target of $878.38.

Analyzing Analyst Ratings: A Detailed Breakdown

Delve into the insights of financial experts and analysts as we provide a comprehensive breakdown of their recent evaluations for Regeneron Pharmaceuticals. Our Ratings Table below offers a detailed overview of the decisions made by key analysts, their current ratings, and price targets. Understanding how these experts perceive the company can yield valuable insights into potential market trends and investor sentiment.

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Regeneron Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Regeneron Pharmaceuticals compared to the broader market.
• Price Targets: Gaining insights, analysts provide estimates for the future value of Regeneron Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.

To gain a panoramic view of Regeneron Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Regeneron Pharmaceuticals analyst ratings.

Get to Know Regeneron Pharmaceuticals Better

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Regeneron Pharmaceuticals: Financial Performance Dissected

Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.

Revenue Growth: Regeneron Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 14.53%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Regeneron Pharmaceuticals's net margin excels beyond industry benchmarks, reaching 29.97%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Regeneron Pharmaceuticals's ROE excels beyond industry benchmarks, reaching 4.12%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Regeneron Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 3.21%. This signifies efficient management of assets and strong financial health.

Debt Management: Regeneron Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.11, reflecting a lower dependency on debt financing and a more conservative financial approach.

Analyst Ratings: What Are They?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.